Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SRPT - US8036071004 - Common Stock

21.49 USD
-0.33 (-1.51%)
Last: 12/30/2025, 8:00:01 PM
21.38 USD
-0.11 (-0.51%)
After Hours: 12/30/2025, 8:00:01 PM
Fundamental Rating

3

SRPT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year SRPT has reported negative net income.
SRPT had a negative operating cash flow in the past year.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

With an excellent Return On Assets value of -7.77%, SRPT belongs to the best of the industry, outperforming 84.91% of the companies in the same industry.
With an excellent Return On Equity value of -20.57%, SRPT belongs to the best of the industry, outperforming 83.02% of the companies in the same industry.
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 76.25%, SRPT belongs to the best of the industry, outperforming 84.15% of the companies in the same industry.
SRPT's Gross Margin has been stable in the last couple of years.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
The number of shares outstanding for SRPT has been increased compared to 5 years ago.
Compared to 1 year ago, SRPT has an improved debt to assets ratio.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 0.00, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SRPT (0.00) is better than 60.19% of its industry peers.
A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
SRPT has a worse Debt to Equity ratio (0.78) than 73.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 0
ROIC/WACCN/A
WACC7.4%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

SRPT has a Current Ratio of 2.95. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
SRPT's Current ratio of 2.95 is on the low side compared to the rest of the industry. SRPT is outperformed by 65.09% of its industry peers.
SRPT has a Quick Ratio of 1.79. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
SRPT has a worse Quick ratio (1.79) than 76.98% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 1.79
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 47.15%.
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%

3.2 Future

The Earnings Per Share is expected to grow by 2.74% on average over the next years.
The Revenue is expected to decrease by -5.76% on average over the next years.
EPS Next Y-338%
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
EPS Next 5Y2.74%
Revenue Next Year13.31%
Revenue Next 2Y-8.22%
Revenue Next 3Y-7.29%
Revenue Next 5Y-5.76%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 9.15, the valuation of SRPT can be described as reasonable.
SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. SRPT is cheaper than 98.68% of the companies in the same industry.
SRPT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.35.
Industry RankSector Rank
PE N/A
Fwd PE 9.15
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

SRPT's earnings are expected to decrease with -6.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.49%
EPS Next 3Y-6.52%

More info and screens

0

5. Dividend

5.1 Amount

SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (12/30/2025, 8:00:01 PM)

After market: 21.38 -0.11 (-0.51%)

21.49

-0.33 (-1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners84.86%
Inst Owner Change1.89%
Ins Owners4.62%
Ins Owner Change19.41%
Market Cap2.25B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68.24
Price Target30.15 (40.3%)
Short Float %20.17%
Short Ratio4.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)-5.86%
PT rev (3m)-10.53%
EPS NQ rev (1m)2.17%
EPS NQ rev (3m)-34.86%
EPS NY rev (1m)-23.42%
EPS NY rev (3m)-20.97%
Revenue NQ rev (1m)0.4%
Revenue NQ rev (3m)8.32%
Revenue NY rev (1m)3.2%
Revenue NY rev (3m)2.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.15
P/S 0.93
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.75
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)2.35
Fwd EY10.93%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.25%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 290.01%
Cap/Sales 5.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 1.79
Altman-Z 0
F-Score3
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-338%
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
EPS Next 5Y2.74%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year13.31%
Revenue Next 2Y-8.22%
Revenue Next 3Y-7.29%
Revenue Next 5Y-5.76%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-278.15%
EBIT Next 3Y9.2%
EBIT Next 5Y11.92%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRPT.


What is the valuation status of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.


How profitable is SAREPTA THERAPEUTICS INC (SRPT) stock?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.


What is the earnings growth outlook for SAREPTA THERAPEUTICS INC?

The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -338% in the next year.